Exiproben

Exiproben

SCHEMBL1643758

CCCCCCOCC(O)COc1ccccc1C(=O)O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ NR1I2 O75469 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ CHRM2 P08172 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ ADRA2A P08913 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ OPRK1 P41145 1/20 0.54
▸ HTR2B P41595 1/20 0.54
▸ SLC6A3 Q01959 1/20 0.54
▸ HDAC6 Q9UBN7 1/20 0.54
▸ PLA2G4B P0C869 1/20 0.53
▸ PTPN11 Q06124 3/20 0.52
▸ KDM4E B2RXH2 1/20 0.51
▸ RECQL P46063 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.50
▸ PTK2B Q14289 1/20 0.50
▸ ABCB1 P08183 4/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28965964 0.87 TSHR (0.52) KMT2AMEN1NR1I2LMNACHRM2
SCHEMBL8861924 0.84 ALDH1A1 (0.67) KMT2AMEN1NR1I2LMNACHRM2
SCHEMBL18140779 0.84 KMT2A (0.74) KMT2AMEN1NR1I2LMNACHRM2
SCHEMBL8859205 0.84 KMT2A (0.74) KMT2AMEN1NR1I2LMNACHRM2
SCHEMBL6688170 0.84 KMT2A (0.74) KMT2AMEN1NR1I2LMNACHRM2
SCHEMBL2047269 0.84 KMT2A (0.74) KMT2AMEN1NR1I2LMNACHRM2
SCHEMBL1005992 0.84 KMT2A (0.74) KMT2AMEN1NR1I2LMNACHRM2
SCHEMBL2550439 0.84 KMT2A (0.74) KMT2AMEN1NR1I2LMNACHRM2
SCHEMBL6575990 0.84 KMT2A (0.74) KMT2AMEN1NR1I2LMNACHRM2
SCHEMBL342176 0.84 KMT2A (0.74) KMT2AMEN1NR1I2LMNACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150328323-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents SATYAM APPARAO (IN) 2015-11-19 — — US claimed
WO-2014111957-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS SATYAM APPARAO (IN) 2014-07-24 — — WO claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 — — CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed
US-10877035-B2 Advanced drug development and manufacturing ICAGEN, LLC (US) 2020-12-29 — — US disclosed
US-20200197310-A1 Technology for Preparation of Macromolecular Microspheres NEXBIO, INC. 2020-06-25 — — US disclosed
US-10583086-B2 Technology for preparation of macromolecular microspheres ANSUN BIOPHARMA, INC. (US) 2020-03-10 — — US disclosed
US-10231938-B2 Transdermal drug delivery device including an occlusive backing NOVEN PHARMACEUTICALS, INC. (US) 2019-03-19 — — US disclosed
US-20180125986-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents SATYAM APPARAO (IN) 2018-05-10 — — US disclosed
US-20180071219-A1 Technology for Preparation of Macromolecular Microspheres NEXBIO, INC. 2018-03-15 — — US disclosed
US-20180028449-A1 Technology for the Preparation of Microparticles NEXBIO, INC. 2018-02-01 — — US disclosed
US-6024976-A TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH NOVEN PHARMACEUTICALS, INC. (US) 2000-02-15 — — US disclosed
WO-1999015210-A2 BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS NOVEN PHARMACEUTICALS, INC. (US) 1999-04-01 — — WO disclosed
US-5719197-A DRUG DELIVERY NOVEN PHARMACEUTICALS, INC. (US) 1998-02-17 — — US disclosed
US-5656286-A BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE NOVEN PHARMACEUTICALS, INC. (US) 1997-08-12 — — US disclosed
WO-1996040084-A1 COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT NOVEN PHARMACEUTICALS, INC. (US) 1996-12-19 — — WO disclosed
WO-1996040086-A2 COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS NOVEN PHARMACEUTICALS, INC. (US) 1996-12-19 — — WO disclosed
US-5446070-A Flexible, finite, bioadhesive, therapeutical agent in solid form NOVER PHARMACEUTICALS, INC. (US) 1995-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180125986-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents NOS2, NOS1, NOS3 KMT2A 4386/4885MEN1 2169/4885NR1I2 1730/4885
US-20150328323-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents NOS2, NOS1, PTGIS KMT2A 4534/4885MEN1 2312/4885NR1I2 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback